New hope for rare cholesterol disease: drug slashes dangerous LDL levels
NCT ID NCT06723652
First seen Oct 31, 2025 · Last updated May 25, 2026 · Updated 21 times
Summary
This study tested a new medicine called SHR-1918 in 55 people with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that causes extremely high cholesterol and early heart disease. Participants received either the drug or a placebo, and researchers measured how much their LDL (bad) cholesterol dropped after 12 weeks. The goal is to see if SHR-1918 can help control cholesterol levels in people who already take other cholesterol-lowering medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Second Xiangya Hospital of Central South University Hospital
Changsha, Hunan, 410000, China
Conditions
Explore the condition pages connected to this study.